drugset / Trial / NCT01113502
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I/II open label study being conducted to evaluate the overall safety and initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an investigational drug, which means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in this type of disease. Approximately 35 people will be enrolled on this study at the University of Pennsylvania
Timeline
- Start
- 2010-06
- Primary completion
- 2013-03-14
- Completion
- 2015-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 50 mg | Oral |
| Subject | Eltrombopag | Small molecule | 100 mg | Oral |
| Subject | Eltrombopag | Small molecule | 200 mg | Oral |
| Subject | Eltrombopag | Small molecule | 300 mg | Oral |